96988 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Vasoactive intestinal peptide [VIP]; Related peptides
EFFECTIVE TRUNCATED PACAPS FOR DISEASE MODIFYING TREATMENT OF NEURODEGENERATIVE DISEASES
#2STABILIZED PACAP PEPTIDE
#3MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
#4COMPOSITIONS AND USES OF VASOACTIVE INTESTINAL PEPTIDE (VIP) ANTAGONISTS
#5HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME
#6GLYCOPEPTIDES AND USES THEREOF
#7MICROORGANISM EXPRESSING VASOACTIVE INTESTINAL PEPTIDE, AND USE THEREOF
#8POEGMA COPOLYMER CONJUGATES AND METHODS OF TREATING DISEASES
#9ELEVATED INTRACRANIAL PRESSURE TREATMENT
#10COILED COIL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF
#11MIRAC PROTEINS
#12RECOMBINANT PROTEIN COMPRISING MULTIPLE MULTI-PEPTIDE SETS, PHARMACEUTICAL COMPOSITION COMPRISING THE RECOMBINANT PROTEIN, AND METHOD FOR PREPARING THE RECOMBINANT PROTEIN
#13RECOMBINANT PROTEIN COMPRISING MULTIPLE MULTI-PEPTIDE SETS, PHARMACEUTICAL COMPOSITION COMPRISING THE RECOMBINANT PROTEIN, AND METHOD FOR PREPARING THE RECOMBINANT PROTEIN
#14PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME
#15GLYCOPEPTIDE ANALOGS OF SECRETIN FAMILY PEPTIDES
#16Anti-PACAP antibodies and uses thereof
#17SATIATION PEPTIDES FOR WEIGHT LOSS AND ALTERED TASTE SENSITIVITY
#18PAC1 receptor agonists (MAXCAPs) and uses thereof
#19VASOACTIVE INTESTINAL PEPTIDE (VIP) FOR USE IN THE TREATMENT OF DRUG-INDUCED PNEUMONITIS
#20Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof
#21MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
#22Compositions and uses of vasoactive intestinal peptide (VIP) antagonists
#23Screening method for identifying anti-PACAP antibodies or antibody fragments suitable for use in treating or preventing PACAP-associated photophobia or light aversion
#24Methods of treatment with anti-PACAP antibodies
#25HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME
#26Elevated intracranial pressure treatment
#27Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof
#28Peptides comprising non-natural amino acids and methods of making and using the same
#29Triblock peptide amphiphiles, micelles and methods of use
#30Nanoparticles conjugated with vasoactive intestinal peptide antagonists
#31ANTI-SERUM ALBUMIN BINDING VARIANTS
#32METHOD FOR PREPARING LIXISENATIDE
#33Coiled coil immunoglobulin fusion proteins and compositions thereof
#34Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes
#35Anti-PACAP antibodies
#36Ligands Modified by Circular Permutation as Agonists and Antagonists
#37Method of preparing peptides comprising a lipophilically modified lysine side chain
#38PAC1 receptor agonists (MAXCAPS) and uses thereof
#39High-activity long-acting hypoglycemic fusion protein as well as preparation method and medical application thereof
#40AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
#41PAC1 antibodies and uses thereof
#42Generating targeted sequence diversity in fusion proteins
#43FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME
#44PEPTIDE AGONISTS OF GLP-1 ACTIVITY
#45Peptides comprising non-natural amino acids and methods of making and using the same
#46Highly active polypeptides and methods of making and using the same
#47Compounds as peptidic GLP1/glucagon/GIP receptor agonists
#48Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists
#49Generating targeted sequence diversity in fusion proteins
#50Liquid formulation of long acting insulinotropic peptide conjugate
#51Mirac proteins
#52Satiation peptides for weight loss and altered taste sensitivity
#53Anti-serum albumin binding variants
#54Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
#55Stabilized insulinotropic peptides and methods of use
#56Elevated intracranial pressure treatment
#57Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical composition for preventing or treating diabetes, containing same as active ingredient
#58AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
#59Use of modified vasoactive intestinal peptides in the treatment of hypertension
#60Mirac proteins
#61Ligands modified by circular permutation as agonists and antagonists
#62Enterokinase cleavable polypeptides
#63PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF
#64Fusion polypeptides comprising mucin-domain polypeptide linkers
#65VIP fragments and methods of use
#66Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
#67Coiled coil immunoglobulin fusion proteins and compositions thereof
#68Stabilized insulinotropic peptides and methods of use
#69Anti-serum albumin binding variants
#70Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
#71Peptides comprising non-natural amino acids and methods of making and using the same
#72Exendin-4 derivatives as selective glucagon receptor agonists
#73Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
#74Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
#75Composition for long-acting peptide analogs
#76Glucose-regulating polypeptides and methods of making and using same
#77Generating targeted sequence diversity in fusion proteins
#78Albumin fusion proteins
#79Dual GLP-1/GIP receptor agonists
#80Dual GLP-1/glucagon receptor agonists
#81Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
#82Methods of managing graft versus host disease
#83Use of modified vasoactive intestinal peptides in the treatment of hypertension
#84ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE
#85GLP-1, exendin-4, peptide analogs and uses thereof
#86VIP fragments and methods of use
#87Mirac proteins
#88Mirac proteins
#89Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs for treating contrast-induced nephropathy
#90Albumin fusion proteins
#91Ligands modified by circular permutation as agonists and antagonists
#92Suppression of prostate cancer using a targeted clostridial neurotoxin
#93AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
#94Mirac proteins
#95Engineered polypeptides having enhanced duration of action
#96Treatment of kidney fibrosis with VIP fragments
#97Peptides derivatized with A-B-C-D- and their therapeutical use
#98Site-directed PEG-modified exendin-4 analogs and uses thereof
#99METHOD FOR PREPARING EXENATIDE
#100Methods for treating steatotic disease
#101VIP fragments and methods of use
#102Stabilized insulinotropic peptides and methods of use
#103Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
#104Fusion protein of Exendin-4 and its analog, preparation method and use thereof
#105Highly active polypeptides and methods of making and using the same
#106Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
#107Method for Producing Radioactively Labeled Polypeptide
#108EXENDIN AND EXENDIN AGONISTS FOR EATING DISORDERS
#109GLP-1, exendin-4, peptide analogs and uses thereof
#110GLP-1 compounds
#111Acylated exendin-4 compounds
#112CONJUGATES WITH IMPROVED PHARMACOKINETIC PROPERTIES
#113RADIOLABELED COMPOUND DIRECTABLE IN VIVO TO TARGET TISSUE AND USE THEREOF
#114Mirac proteins
#115Modified exendins and uses thereof
#116Exendin variant and conjugate thereof
#117Mirac proteins
#118GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONISTS FOR TREATING AUTOIMMUNE DISORDERS
#119Stable analogs of peptide and polypeptide therapeutics
#120Peptide derivative and use of the same
#121DETECTION OF NEUROPEPTIDES ASSOCIATED WITH PELVIC PAIN DISORDERS AND USES THEREOF
#122Neuroprotective iron chelators and pharmaceutical compositions comprising them
#123THERAPEUTIC METHOD FOR INCREASING PANCREATIC BETA CELL MASS
#124Albumin fusion proteins
#125Conjugates of GLP-1 agonists and uses thereof
#126EXENDINS AND EXENDIN AGONIST ANALOGS TO REGULATE GASTROINTESTINAL MOTILITY
#127PROCESS FOR THE PRODUCTION OF PREFORMED CONJUGATES OF ALBUMIN AND A THERAPEUTIC AGENT
#128CGRP antibodies
#129Anti-serum albumin binding variants
#130Protracted exendin-4 compounds
#131Anti-serum albumin binding variants
#132Treatment of renal dysfunction and multiple myeloma using PACAP compounds
#133PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF
#134Methods for Lowering Plasma Glucagon with Exendins and Exendin Agonist Analogs
#135Exendin polypeptide linked to biotin, method for the preparation thereof and pharmaceutical composition comprising the same
#136Fusion protein of an exendin to modified transferrin
#137PEPTIDE AGONISTS OF GLP-1 ACTIVITY
#138Treatment of kidney disorders with VIP fragments
#139Composition for long-acting peptide analogs
#140Polypeptides that bind to and inhibit secretion from growth hormone secreting cells
#141PEPTIDE AGONISTS OF GLP-1 ACTIVITY
#142DPP-IV resistant GIP hybrid polypeptides with selectable properties
#143Exendin agonist compounds
#144GLP-1 Derivatives II
#145PROCESS FOR THE PRODUCTION OF EXENATIDE AND OF AN EXENATIDE ANALOGUE
#146Exendin and exendin agonists for eating disorders
#147MOLECULAR PROBE FOR IMAGING OF PANCREATIC ISLET AND THE PRECURSOR, AND USE OF THE SAME
#148DRUG FUSIONS AND CONJUGATES
#149Long-acting transient polymer conjugates of exendin
#150Albumin fusion proteins
#151Glucose-regulating polypeptides and methods of making and using same
#152Method of Purifying a Peptide
#153Method for amidating polypeptides with basic amino acid C-terminals by means of specific endoproteases
#154PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE
#155Mirac Proteins
#156ANALOGUES OF EXENDIN-4 AND EXENDIN-3
#157Peptides with improved properties having the biological activity of vasoactive intestinal peptide (VIP) and their use for the treatment of lung diseases
#158PEG modified exendin or exendin analog and compositions and use thereof
#159N-terminal modified exendin-4
#160Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
#161Insulinotropic complex using an immunoglobulin fragment
#162Method for producing acylated peptides
#163Biosynthetic Polypeptides Utilizing Non-Naturally Encoded Amino Acids
#164SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS
#165Composition and Methods for Treatment of Congestive Heart Failure
#166Modified exedins and uses thereof
#167Acylated Exendin-4 Compounds
#168Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
#169Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonists and their pharmacological methods of use
#170GLP-1, exendin-4, peptide analogs and uses thereof
#171Fusion protein of exendin-4 to a transferrin (Tf) polypeptide
#172DNA Vaccine for Cancer Therapy
#173Lyophilized formulations of exendins and exendin agonist analogs
#174STABILIZED EXENDIN-4 COMPOUNDS
#175Peptide derivatives of exendin-4
#176Exendin agonist analogs to treat diabetes
#177PACAP for aquatic organism culture
#178Modified therapeutic peptides with extended half-lives in vivo
#179VASOACTIVE INTESTINAL POLYPEPTIDE COMPOSITIONS
#180Exendins and exendin agonist analogs to regulate gastrointestinal motility
#181Pituitary Adenylate Cyclase Activating Peptide (PACAP) Receptor (VPAC2) Agonists and Their Pharmacological Methods of Use
#182Albumin Fusion Proteins
#183Protection of exendin-4 peptides through conjugation
#184Albumin Fusion Proteins
#185Composition for long-acting peptide analogs
#186SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS
#187Long lasting synthetic exendin-4 peptide conjugates and methods of use thereof
#188Dimeric Peptide Agonists of the Glp-1 Receptor
#189Novel exendin agonist compounds
#190Composition and method for prevention and treatment of type I diabetes
#191VIP fragments and methods of use
#192NOVEL GLP-1 ANALOGUES LINKED TO ALBUMIN-LIKE AGENTS
#193Method for producing carboxy-terminal-amidified peptides
#194High purity peptides
#195Pegylation of Vasoactive Intestinal Peptide (Vip) / Pituitary Adenylate Cyclase Activating Peptide (Pacap) Receptor 2 (Vpac2) Agonists and Methods of Use
#196Exendin Analog Formulations
#197Protracted exendin-4 compounds
#198Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
#199VASOACTIVE INTESTINAL POLYPEPTIDE COMPOSITIONS
#200Albumin fusion proteins
#201Selective Apac2 Receptor Peptide Agonists
#202Albumin Fusion Proteins
#203Albumin fusion proteins comprising insulin polypeptides
#204Albumin Fusion Proteins
#205G-CSF-albumin fusion proteins
#206Albumin fusion proteins
#207Exendin agonist compounds
#208GLP-1 derivatives II
#209SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS
#210Cyclic vasoactive intestinal peptide receptor-2 agonists
#211Selective Vpac2 Receptor Peptide Agonists
#212Detection of neureopeptides associated with pelvic pain disorders and uses thereof
#213Stable analogs of peptide and polypeptide therapeutics
#214Method For Producing Acylated Peptides
#215Selective Vpac2 Receptor Reptide Agonists
#216Vasoactive Intestinal Polypeptide Compositions
#217Process for the production of preformed conjugates of albumin and a therapeutic agent
#218Albumin fusion proteins
#219Albumin fusion proteins
#220Method of Enhancing Neural Stem Cell Proliferation, Differentiation, and Survival Using Pituitary Adenylate Cyclase Activating Polypeptide (PACAP)
#221Peptide agonists of GLP-1 activity
#222Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
#223Novel GLP-1 analogues linked to albumin-like agents
#224Novel GLP-1 compounds
#225Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
#226Methods for glucagon suppression using modified exendins
#227Exendin 4 polypeptide fragment
#228Exendin agonist compounds
#229Albumin fusion proteins
#230Peptides and medicinal compositions containing the same
#231Vasoactive intestinal polypeptide pharmaceuticals
#232Neuroprotective iron chelators and pharmaceutical compositions comprising them
#233Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung diseases
#234Albumin fusion proteins
#235Stabilized Exendin-4 compounds
#236Novel exendin agonist formulations and methods of administration thereof
#237Use of exendins and agonists thereof to treat diabetes
#238Methods involving long lasting synthetic exendin-4 peptide conjugates
#239Hybrid polypeptides with selectable properties
#240Transepithelial delivery of peptides with incretin hormone activities
#241Vasoactive intestinal polypeptide pharmaceuticals
#242Exendin analog formulations
#243Methods involving long lasting synthetic exendin-4-peptide conjugates
#244Short-warp peptide-dye conjugate as contrast agent for optical diagnostic
#245Biosynthetic polypeptides utilizing non-naturally encoded amino acids
#246Long lasting synthetic exendin-4 peptide conjugates
#247Peptide compositions with effects on blood glucose
#248Pharmaceutical compositions containing exendins
#249VPAC1 selective antagonists and their pharmacological methods of use
#250Albumin fusion proteins comprising GLP-1 polypeptides
#251Methods for glucagon suppression using modified exendins
#252Use of exendins and agonists thereof for lowering plasma lipid
#253Compositions and methods for treating ileus
#254Chemically modified metabolites of regulatory peptides and methods of producing and using same
#255Exendins, exendin agonists, and methods for their use
#256Stable analogs of peptide and polypeptide therapeutics
#257Exendins and exendin agonists for weight reduction and obesity
#258Peptides comprising furanoid sugar amino acids for the treatment of cancer
#259Formulation strategies in stabilizing peptides in organic solvents and in dried states